← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #95 OF 1,000 MOST-CITED

Process control procedures, Lack of or inadequate procedures

FDA cited this observation 235 times across 226 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Devices235
BY FISCAL YEAR
FY20265
FY202524
FY202426
FY202324
FY202222
FY20213
FY202022
FY201936
FY201841
FY201732

How FDA worded it — real examples

Process control procedures that describe any process controls necessary to ensure conformance to specifications have not been established.

Marson Medical, Inc. · Paramus, New Jersey · Devices · 2026-01-16

Process control procedures that describe any process controls necessary to ensure conformance to specifications have not been adequately established.

Specialty Health Products CO, LLC · Phoenix, Arizona · Devices · 2025-12-11

Process control procedures that describe any process controls necessary to ensure conformance to specifications have not been adequately established.

GRAMERCY EXTREMITY ORTHOPEDICS · Richardson, Texas · Devices · 2025-10-24

Process control procedures that describe any process controls necessary to ensure conformance to specifications have not been adequately established.

Medaesthetics International, LLC · Phoenix, Arizona · Devices · 2025-10-22

Process control procedures that describe any process controls necessary to ensure conformance to specifications have not been adequately established.

Stephen Gould Corporation · Gahanna, Ohio · Devices · 2025-10-10

Process control procedures that describe any process controls necessary to ensure conformance to specifications have not been adequately established.

ANDERSEN CALEDONIA LTD · Bellshill · Devices · 2025-09-18

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharmaceutical quality systemMedical devices

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →